Arie Belldegrun Net Worth (Updated 2026).

Arie Belldegrun, a prominent figure in the biotechnology industry, began his career in the 1980s, armed with a Ph.D. in immunology from the Weizmann Institute of Science in Israel. He started as a postdoctoral fellow at the National Institutes of Health in Bethesda, Maryland, where he honed his skills in immunology and cancer research.

Belldegrun’s breakthrough came in the late 1980s when he co-founded Kite Pharma, a pioneering company in the field of chimeric antigen receptor (CAR) T-cell therapy. This revolutionary approach involves engineering a patient’s own immune cells to fight cancer, marking a significant advancement in cancer treatment. Kite Pharma’s success, including its acquisition by Gilead Sciences for $11.9 billion in 2017, catapulted Belldegrun into the limelight, establishing him as a leading figure in the biotech industry.

Arie Belldegrun’s Current Net Worth (2025)

As of 2025, Arie Belldegrun’s net worth is estimated to be around $15 billion, according to Forbes. This significant wealth is primarily attributed to his successful career in the healthcare industry, particularly in the field of biotechnology.

Career

Arie Belldegrun is a renowned Israeli-American businessman and philanthropist. He is the co-founder and former CEO of Amgen, a multinational biotechnology company. Under his leadership, Amgen grew from a startup to a global leader in biotechnology, with a market capitalization of over $100 billion. He retired from Amgen in 2012 but continues to be involved in various healthcare ventures.

Other Ventures

After leaving Amgen, Belldegrun founded several other biotechnology companies, including Kite Pharma and Allogene Therapeutics. Kite Pharma was acquired by Gilead Sciences in 2017 for approximately $11.9 billion. Allogene Therapeutics, focused on allogeneic CAR T-cell therapies, is a publicly traded company with a market capitalization of over $5 billion.

Assets

Belldegrun’s assets include significant stakes in several biotechnology companies, as well as real estate holdings. He owns a sprawling estate in Beverly Hills, California, valued at over $50 million. He also has philanthropic assets, including the Belldegrun Foundation, which supports various charitable causes, particularly in the fields of healthcare and education.

Annual Income

Arie Belldegrun’s annual income is not publicly disclosed. However, as a successful businessman and investor in the biotechnology industry, his income is likely substantial. His wealth has primarily been generated through the success of the companies he has founded and led, rather than through a high annual salary. His current net worth is a testament to his long-term success in the industry.

Frequently Asked Questions about  Arie Belldegrun

**Frequently Asked Questions: Arie Belldegrun Net Worth**

1. What is Arie Belldegrun’s net worth?

Arie Belldegrun’s net worth is estimated to be around $2.5 billion.

2. How did Arie Belldegrun make his fortune?

Belldegrun made his fortune primarily through his work in the biotechnology industry. He co-founded several successful biotechnology companies, including Kite Pharma and Juno Therapeutics.

3. What is Arie Belldegrun’s background?

Belldegrun was born in Israel and moved to the United States to attend medical school. He is a physician and immunologist by training, with a focus on cancer research.

4. What companies has Arie Belldegrun founded?

Belldegrun has co-founded several companies, including Kite Pharma, Juno Therapeutics, and Allogene Therapeutics.

5. What is Arie Belldegrun’s role at his companies?

Belldegrun serves as the Chairman and CEO of Allogene Therapeutics. He has also held executive roles at Kite Pharma and Juno Therapeutics.

6. What are Arie Belldegrun’s companies known for?

Belldegrun’s companies are known for their work in developing immunotherapies for cancer treatment, particularly using chimeric antigen receptor (CAR) T-cell therapy.

7. What awards has Arie Belldegrun won?

Belldegrun has been recognized with several awards, including the Ernst & Young Entrepreneur Of The Year Award and the Biotechnology Innovation Organization’s (BIO) Biotechnology Pioneer Award.

8. What is Arie Belldegrun’s education background?

Belldegrun received his medical degree from the Hebrew University of Jerusalem and completed his residency and fellowship at the University of California, Los Angeles (UCLA).

9. What is Arie Belldegrun’s philanthropic work?

Belldegrun and his wife, Jeri, have established the Belldegrun Research Foundation, which supports cancer research and other charitable causes.

10. What is Arie Belldegrun’s current focus?

Belldegrun’s current focus is on leading Allogene Therapeutics, a company developing off-the-shelf CAR T-cell therapies for cancer treatment.